Differentiation T Lymphocyte cells expressing Interleukin-17 Percentage On Healthy Person and Adult Acute Myeloid Leukemia Patient

Elvan Dwi Widyadi, Yetti Hernaningsih, Endang Retnowati, Ugroseno Ugroseno, Ryzky Widi Atmaja

Abstract


Acute Mieloid Leukemia (AML) is a hematologic cause of cancer deaths of 1.2% including a relatively rare disease but by the end of the decade there is an increase in the number of new cases. The immune system in AML is caused by gene mutations giving immunosuppressive effects so that the immune system will be inhibited in eliminating leukemia cells. The immune response of tumors is important to determine the prognosis, development of new cancer immunotherapy as well. One of the subset of lymphocytes T is  gdT lymphocyte cell with innate nature, but until now no information is required about gdT cell profile in AML patients. gdT cells have properties as antitumors played by Interferon production g (INF g), and the nature of protumor by interleukin 17 (IL-17). The percentage of lymphocyte T (CD3 +) of AML patients and healthy people did not differ (p = 0.528), indicating, not being activated for proliferation. gdT Lymphocyte cells percentage in healthy people by race, genetic and exposure to the surrounding environment such as infection. Percentage of gdT lymphocyte of AML patients and healthy people was not different from (p = 0.694), showed an immune response by gdT cells Unefected to proliferate. The percentage of gdT llimfocytes expressing the interleukin 17 (gdT17 cells)in patients AML and healthy people did not differ significantly (p = 0.436), this indicates inhibited proliferation.


Keywords


Acute Mieloid Leukemia, T lymphocytes, T cells, T cells, IL-17

Full Text:

PDF

References


Aswald JM, Wang XH, Aswald S, Lutynski A, Minden MD, Messner HA, Keating A. 2006. Flow Cytometric Assessment of Autologous  T Cells in Patients with Acute Myeloid Leukemia: Potential Effector Cells for Immunotherapy? Cytometry Part B (Clinical Cytometry) 70B:379–390 (2006) DOI: 10.1002/cyto.b.20115

Austin, R. 2016. Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol/Hematol (2016), http://dx.doi.org/ 10.1016/ j.critrevonc. 2016.04.020

Bruno Silva-Santos, K. S. (2015).  T cells in cancer. Nature Reviews Immunology doi:10.1038/nri3904

Esin S, Shigematsu M, Nagai S, Wigzell H, Grunewald J. Different Percentage of Peripheral Blood T Cells in Healthy Individuals from Different Areas of the Worlds. Scand J Immunol 1996; 43:593-596

Hiddemann, W. (2016). Handbook of acute leukemia. Munich German: Springer International Publishing Switzerland, P. 3-6.

Ismail, M. T. Mona A. (2013). Role of T-helper 17 cells and interleukin-17 expression in patients with acute myeloid leukemia. Egyptian Journal of Haematology , 38:47–50.

Meeh PF, Michelle K, Rebecca LO, S Muga, Philip B, Neuberg R, Lamb LP. 2006. Characterization of the  T cell response to acute leukemia. Cancer Immunol Immunother (2006) 55: 1072–1080 DOI 10.1007/s00262-005-0094-6

Panoskaltsis N, Reid CDL, Knight SC. 2003. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia. Leukemia (2003) 17, 716–730. doi: 10.1038/sj.leu.2402835

Raulet DH. 1989. The structure, function, and molecular genetics of the gamma/delta T cell receptor. Annu Rev Immunol 1989; 7:175-207

Subklewe M (2016). Future outlook for acute leukemias. Handbook of acute leukemia. Munich German: Springer International Publishing Switzerland 2016. P 7.

Wakita D et al. (2010). Tumor-infiltrating IL-17-producing  T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 2010. 40: 1927–1937 DOI 10.1002/eji.200940157




DOI: http://dx.doi.org/10.24293/ijcpml.v25i2.1383

Refbacks

  • There are currently no refbacks.